iCAD Reports Significantly Improved Medicare Payment for Intraoperative Radiation Therapy

Final 2013 Reimbursement Rate for Treatment Delivery is Double the Value in the Proposed Rule, Will Encourage Use of iCAD’s Innovative Radiation Therapy Treatment

iCAD, Inc. (ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced the U.S. Centers for Medicare & Medicaid Services (CMS) has issued an improved payment policy for Intraoperative Radiation Therapy (IORT), which is delivered by the Company’s Xoft® Axxent® Electronic Brachytherapy System®. In the 2013 Final Rule issued November 1, 2012, CMS unpackaged the IORT payment codes and assigned a distinct payment value for IORT treatment delivery. CMS assigned IORT treatment delivery to the same ambulatory payment classification as Stereotactic Radiosurgery, MRgFUS and MEG, Level 1.

Gentiva® Health Services Reports Third Quarter 2012 Results

Gentiva Health Services, Inc. (GTIV), the largest provider of home health and hospice services in the United States based on revenue, today reported third quarter 2012 results.  Quarterly highlights include:

• Total net revenues of $424.4 million.
• Adjusted income from continuing operations on a diluted per share basis of $0.32.
• Adjusted EBITDA of $46.1 million.
• Free cash flow of $23.2 million.

  Published: 01 November 2012

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: Gentiva Health Services Inc ( GTIV )

CollabRx Partners with Life Technologies in Molecular Diagnostics

Life Technologies’ Cancer Panels to be paired with CollabRx’s Interpretive Analytics

CollabRx, Inc. (CLRX) today announced a multi-year partnership agreement with Life Technologies Corporation for development and commercialization of CollabRx technology and content resources to be used in conjunction with Life Technologies’ global cancer diagnostics development and its laboratory developed test services business. The agreement represents a major step forward by CollabRx in providing laboratories and next-generation sequencing (NGS) companies with meaningful insights into cancer.

Complete Genomics and BGI-Shenzhen Announce Definitive Agreement to Merge

Combination Will Create a Global Innovator in Whole Human Genomic Sequencing

Complete Genomics, Inc. (GNOM) ("Complete"), an innovative leader in whole human genomic sequencing, and BGI-Shenzhen ("BGI"), a leading international genomics company based in Shenzhen, China, today announced that they have entered into a definitive merger agreement. Through this agreement, a wholly-owned U.S. subsidiary of BGI will launch a tender offer to purchase all outstanding shares of common stock of Complete for $3.15 per share in cash, without interest. This price represents approximately a 54% premium to the $2.04 closing price per share of Complete common stock on June 4, 2012, the last trading day prior to Complete's announcement that it was undertaking an evaluation of strategic alternatives to secure the financial resources needed for continued commercialization of its technology.